LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Tolley, Caroline (2015)
Languages: English
Types: Doctoral thesis
Subjects: R, T

Classified by OpenAIRE into

mesheuropmc: hemic and lymphatic diseases, congenital, hereditary, and neonatal diseases and abnormalities, animal diseases
Production of recombinant FVIII, the protein that is missing or dysfunctional in haemophilia A patients, is highly inefficient compared to other recombinant clotting factors such as FIX. This is predominantly due to complex intracellular trafficking, short half-life and protein instability. This study aimed to increase the amount of functional FVIII produced in mammalian cells by co-expression with anti-FVIII Camelid antibody fragments (VHH). Three VHH ligands were supplied by BAC BV (as DNA constructs), two of which when expressed in yeast are known to bind recombinant FVIII (ligands 2 and 7) and are used commercially as FVIII purification tools. From these three constructs, nine new VHH plasmids constructs were designed and transiently expressed in a stable BHK-human FVIII-expressing cell line.\ud Of the nine VHH fragments that were co-expressed in the BHK FVIII cell line, four of these had a statistically significant impact on the ‘clotting time’ of the cell media as demonstrated by the activated partial thromboplastin time assay (aPTT). Two ligand 2 constructs (L2C1 and L2C2) prolonged the coagulation time by 4 seconds (P-value 0.0001, 95% confidence intervals 38.5-43.5), and 3.4 seconds (P-value 0.0072, 95% CI 36.5-40.3) respectively, indicating a decrease in functional FVIII activity versus media from the untransfected and null transfected BHK-FVIII cell line. Two ligand 7 constructs (L7C1 and L7C3) caused a decrease in coagulation time of 3.2 seconds (P=0.0057, 95% CI 30.5-33.3), and 4 seconds (P=0.0002, 95% CI 29.1-32.9) respectively, indicating an increase in functional FVIII activity versus media from the untransfected and null transfected BHK-FVIII cell line.\ud Ligand 7 and ligand 2 both bind to the FVIII light chain, albeit in different regions and with different affinities (data confidential to BAC BV). BAC studies showed that ligand 7 competes with vWF on the FVIII light chain, which is known to increase stability of FVIII in vivo, whereas ligand 2 does not compete for this binding site. The opposing effects of ligand 7 and ligand 2 on FVIII clotting times seen in this study could be due to their differences in FVIII binding properties, since it is known that binding location of FVIII ligands can have an impact on FVIII clotting activity.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Braakman, I. and N. J. Bulleid (2011). Protein Folding and Modification in the Mammalian Endoplasmic Reticulum. Annual Review of Biochemistry, Vol 80. R. D. Kornberg, C. R. H.
    • Raetz, J. E. Rothman and J. W. Thorner. 80: 71-99.
    • Brandizzi, F, and Barlowe, C. (2013). Organization of the ER Golgi interface for membrane traffic control. Nature Reviews Molecular Cell Biology 14, 382-392.
    • Burnouf, T. and M. Radosevich (2001). "Affinity chromatography in the industrial purification of plasma proteins for therapeutic use." Journal of Biochemical and Biophysical Methods 49(1-3): 575-586.
    • Bustin, S. (2002). "Quantification of mRNA using real-time reverse transcription PCR (RTPCR): trends and problems." Journal of Molecular Endocrinology 29(1): 23-39.
    • Butash, K. A., et al. (2000). "Reexamination of the effect of endotoxin on cell proliferation and transfection efficiency." Biotechniques 29(3): 610-614, 616, 618-619.
    • Cao, W., et al. (2008). "Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13." Proc Natl Acad Sci U S A 105(21): 7416-7421.
    • Carr, M.E. et al (2015). Emerging and future therapies for hemophilia. Journal of Blood Medicine. Volume 6. Pages 245-255.
    • Castaman, G., et al. (2010). "F8 mRNA studies in haemophilia A patients with different splice site mutations." Haemophilia 16(5): 786-790.
    • Lenting, P. J., et al. (2010). "The disappearing act of factor VIII." Haemophilia 16: 6-15.
    • Ley, R., et al. (2003). "Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim." Journal of Biological Chemistry 278(21): 18811-18816.
    • Li, T. F., et al. (2012). "Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes:application to brain imaging." The FASEB Journal 26(10): 3969-3979.
    • Lippincott-Schwartz, J., et al. (2000). "Secretory protein trafficking and organelle dynamics in living cells." Annual Review of Cell Developmental Biology 16: 557-589.
    • Ljung, R. (2009). "Prophylactic therapy in haemophilia." Blood Reviews 23(6): 267-274.
    • Lodish, H., et al. (2000). Golgi and Post-Golgi Protein Sorting and Proteolytic Processing.
    • Lollar, P., et al. (1992). "Coagulant properties of hybrid human/porcine factor VIII molecules." J Biol Chem 267(33): 23652-23657.
    • Metcalf, D. J., et al (2007). Formation and function of Weibel-Palade bodies. Journal of Cell Science. 121 (1), 19-27.
    • Miao, H. Z., et al. (2004). "Bioengineering of coagulation factor VIII for improved secretion." Blood 103(9): 3412-3419.
    • Weibel, E. R. and Palade, G. E. (1964). New cytoplasmic components in arterial endothelia.
    • J. Cell Biol. 23, 101-112.
  • No similar publications.

Share - Bookmark

Download from

Cite this article